Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199086 | 0.89 | PPARG (0.36) | PPARGPPARAKDM4CICAM1SELE | |
| SCHEMBL12876196 | 0.85 | KDM4C (0.33) | PPARGPPARAKDM4CICAM1SELE | |
| SCHEMBL12876229 | 0.83 | NPC1 (0.34) | PPARGPPARAKDM4CICAM1SELE | |
| SCHEMBL15006436 | 0.79 | NPC1 (0.31) | PPARGPPARANPC1RAB9A | |
| SCHEMBL12876144 | 0.78 | RAB9A (0.38) | PPARGPPARAKDM4CICAM1SELE | |
| SCHEMBL1197708 | 0.76 | PPARG (0.34) | PPARGPPARAKDM4CNPC1RAB9A | |
| SCHEMBL1198072 | 0.74 | PPARG (0.34) | PPARGPPARAKDM4CICAM1SELE | |
| SCHEMBL12876150 | 0.71 | FFAR1 (0.36) | PPARGPPARAKDM4CNPC1RAB9A | |
| SCHEMBL12876153 | 0.71 | FFAR1 (0.38) | PPARGPPARAKDM4CICAM1SELE | |
| SCHEMBL13650689 | 0.70 | TACR1 (0.31) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | PPARG 139/4885PPARA 517/4885KDM4C 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.